MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint

This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical...

Related Keywords

Switzerland ,United States ,Mary Jane Elliott ,Kristian Reich ,Moonlake Immunotherapeutics ,Prnewswire Moonlake Immunotherapeutics ,Hidradenitis Suppurativa ,Matthias Bodenstedt ,Matthew Cole ,Drug Administration ,Consilium Strategic Communications ,Investigational New Drug ,Institutional Review ,Hidradenitis Suppurativa Clinical Response ,Chief Scientific Officer ,Global Assessment Score ,Psoriasis Area ,Severity Index ,Securities Litigation Reform Act ,Strategic Communications ,Moonlake Immunotherapeutics Ag ,